289 related articles for article (PubMed ID: 34761362)
1. Ayahuasca for the Treatment of Depression.
Palhano-Fontes F; Soares BL; Galvão-Coelho NL; Arcoverde E; Araujo DB
Curr Top Behav Neurosci; 2022; 56():113-124. PubMed ID: 34761362
[TBL] [Abstract][Full Text] [Related]
2. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
Hamill J; Hallak J; Dursun SM; Baker G
Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant.
Rossi GN; Guerra LTL; Baker GB; Dursun SM; Saiz JCB; Hallak JEC; Dos Santos RG
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358968
[TBL] [Abstract][Full Text] [Related]
4. Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca.
Shinozuka K; Tabaac BJ; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
Am J Ther; 2024 Mar-Apr 01; 31(2):e112-e120. PubMed ID: 38518268
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
McKenna DJ; Towers GH; Abbott F
J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
[TBL] [Abstract][Full Text] [Related]
6. Ayahuasca: Pharmacology, neuroscience and therapeutic potential.
Domínguez-Clavé E; Soler J; Elices M; Pascual JC; Álvarez E; de la Fuente Revenga M; Friedlander P; Feilding A; Riba J
Brain Res Bull; 2016 Sep; 126(Pt 1):89-101. PubMed ID: 26976063
[TBL] [Abstract][Full Text] [Related]
7. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
Cameron LP; Olson DE
ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
[TBL] [Abstract][Full Text] [Related]
8. Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture.
Freedland CS; Mansbach RS
Drug Alcohol Depend; 1999 May; 54(3):183-94. PubMed ID: 10372792
[TBL] [Abstract][Full Text] [Related]
9. Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015.
Heise CW; Brooks DE
J Med Toxicol; 2017 Sep; 13(3):245-248. PubMed ID: 27896660
[TBL] [Abstract][Full Text] [Related]
10. Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.
Barker SA
Psychopharmacology (Berl); 2022 Jun; 239(6):1749-1763. PubMed ID: 35064294
[TBL] [Abstract][Full Text] [Related]
11. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
13. Immunological Modulation and Control of Parasitaemia by Ayahuasca Compounds: Therapeutic Potential for Chagas's Disease.
Katchborian-Neto A; Santos MFC; Vilas-Boas DF; Dos Santos EG; Veloso MP; Bueno PCP; Caldas IS; Soares MG; Dias DF; Chagas-Paula DA
Chem Biodivers; 2022 Oct; 19(10):e202200409. PubMed ID: 36163588
[TBL] [Abstract][Full Text] [Related]
14. Mutagenicity of Ayahuasca and Their Constituents to the Salmonella/Microsome Assay.
Kummrow F; Maselli BS; Lanaro R; Costa JL; Umbuzeiro GA; Linardi A
Environ Mol Mutagen; 2019 Apr; 60(3):269-276. PubMed ID: 30488498
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
[TBL] [Abstract][Full Text] [Related]
16. Biodiversity of β-Carboline Profile of
Santos BWL; Oliveira RC; Sonsin-Oliveira J; Fagg CW; Barbosa JBF; Caldas ED
Plants (Basel); 2020 Jul; 9(7):. PubMed ID: 32660098
[TBL] [Abstract][Full Text] [Related]
17. Ayahuasca: What Healthcare Providers Need to Know.
Goldin D; Salani D
J Addict Nurs; 2021 Apr-Jun 01; 32(2):167-173. PubMed ID: 34060770
[TBL] [Abstract][Full Text] [Related]
18.
Malcolm BJ; Lee KC
Ment Health Clin; 2017 Jan; 7(1):39-45. PubMed ID: 29955496
[No Abstract] [Full Text] [Related]
19. Ayahuasca: A review of historical, pharmacological, and therapeutic aspects.
Ruffell SGD; Crosland-Wood M; Palmer R; Netzband N; Tsang W; Weiss B; Gandy S; Cowley-Court T; Halman A; McHerron D; Jong A; Kennedy T; White E; Perkins D; Terhune DB; Sarris J
PCN Rep; 2023 Dec; 2(4):e146. PubMed ID: 38868739
[TBL] [Abstract][Full Text] [Related]
20. Kinetic profile of N,N-dimethyltryptamine and β-carbolines in saliva and serum after oral administration of ayahuasca in a religious context.
Lanaro R; Mello SM; da Cunha KF; Silveira G; Corrêa-Neto NF; Hyslop S; Cabrices OG; Costa JL; Linardi A
Drug Test Anal; 2021 Mar; 13(3):664-678. PubMed ID: 33119972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
